Assessing the effectiveness of an ayurvedic formulation in treating menstrual problems in women with PCOS

Clinical Evaluation Of The Ayurvedic Formulation NIA/DG/2022/01 In Nashtartava With Special Reference To Polycystic Ovarian Syndrome - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100728

Enrollment

Registered

2026-01-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N915- Oligomenorrhea, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Females with Nashtartava(PCOS) having two out of three criteria (ASRM/ESHRE Rotterdam criteria 2023) Oligo and or anovulation Hyperandrogenism clinically and or biochemically Polycystic ovaries confirmed in USG 2 Duration of flow less than previous normal physiological flow 3 Interval between two cycles exceedingly more than 35 days 4 Female patients of age group between 18to40 years (both married and unmarried)

Exclusion criteria

Exclusion criteria: 1) Other androgen excess disorders such as adrenal hyperplasia, androgen producing tumours, Cushing syndrome 2) Other uncontrolled systemic, and ovulatory disorders such as thyroid dysfunction, hyperprolactinemia etc. 3) Patient having congenital and structural abnormalities of uterus and adnexa. 4) Lactating mother, pregnant women 5) Patient using oral contraceptive pills 6) Patient taking any concomitant medicine.

Design outcomes

Primary

Measure	Time frame
Improvement in menstrual parameter (interval, duration and amount) in females with Nashtartava(PCOS) after administration of trial drug for 3 months. Timepoint: Efficacy of trial drug in females with Nashtartava ( PCOS) after administration for 3 months	—

Secondary

Measure	Time frame
Improvement in other associated clinical features in females with Nashtartava ( PCOS) (i.e. acne, hirsutism, obesity etc.) after administration of trial drug for3 months. Reduction in size and number of poly cystic ovaries appearance in females with Nashtartava ( PCOS) in USG after administration of trial drug for 3 months. Reduction in LH/FSH ratio levels in females with Nashtartava ( PCOS) after administration of trial drug for 3 months. Timepoint: Safety (LFT, RFT) and tolerability of trial drug in females with Nashtartava ( PCOS) after administration for 3 months	—

Measure

Time frame

Improvement in other associated clinical features in females with Nashtartava ( PCOS) (i.e. acne, hirsutism, obesity etc.) after administration of trial drug for3 months. Reduction in size and number of poly cystic ovaries appearance in females with Nashtartava ( PCOS) in USG after administration of trial drug for 3 months. Reduction in LH/FSH ratio levels in females with Nashtartava ( PCOS) after administration of trial drug for 3 months. Timepoint: Safety (LFT, RFT) and tolerability of trial drug in females with Nashtartava ( PCOS) after administration for 3 months

—

Countries

India

Contacts

Public ContactDr Sudipta Kumar Rath

Nayional Institute of Ayurveda, Deemed to be University

sudipt@nia.edu.in9828376668

Outcome results